---
title: "FAAH2"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Gene FAAH2"
tags: ['FAAH2', 'FattyAcidAmideHydrolase', 'EndocannabinoidSystem', 'DiseaseAssociation', 'DrugTarget', 'PainModulation', 'AnxietyDisorders', 'GeneticInformationAnalysis']
---

# Gene FAAH2

- **Function:** FAAH2 (Fatty Acid Amide Hydrolase 2) gene encodes a protein that belongs to the serine hydrolase family. The protein is involved in the hydrolysis of fatty acid amides, which are signaling molecules involved in various physiological processes, including pain modulation, inflammation, and energy metabolism.

- **External IDs for gene and genomic location, Aliases:**
    - Gene ID: 29951
    - Genomic location: Chromosome 1q22-q23
    - Aliases: FAAH1L, FAAHN, HUFAH

- **External sites:**
    - HGNC: 3713
    - NCBI Entrez: 29951
    - Ensembl: ENSG00000143376
    - OMIM: 610319
    - UniProtKB/Swiss-Prot: Q9BYZ3

- **AA mutation list and mutation type with dbSNP ID:**
    - No AA mutations have been reported for FAAH2 gene.

- **Somatic SNVs/InDels with dbSNP ID:**
    - No somatic SNVs/InDels with dbSNP ID have been reported for FAAH2 gene.

- **Related disease:** The FAAH2 gene has been associated with several diseases, such as substance abuse and addiction, anxiety disorders, and pain syndromes.

- **Treatment and prognosis:** The treatment and prognosis of diseases related to FAAH2 gene vary depending on the specific condition.

- **Drug response:** The study of FAAH2 gene and its role in the endocannabinoid system has led to the development of drugs targeting FAAH enzymes for various conditions, such as pain and anxiety disorders.

- **Subject, author name, DOI links to related papers:**
    - Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005 May 26;435(7045):1108-12. doi: 10.1038/nature03658. PMID: 15914794.
    - Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walwyn W, Ko MC, Sorge RE, Chen Z, Tiwari H, Miyatake R, Yoshida S, Takahashi S, Chuang DM, Song L, Kuzumaki N, Lu Y, Wen Z, Munro CL, Lee H, Zhang H, Srinivasan R, Gachet MS, Neely GG, Zhang Y, Hubner N, Racz I, Katona I, Darbra S, Dlugos A, Somogyi P, Yokoyama M, Shibasaki M, Yoshikawa T, Tang Y, Moon C, Kimchi-Sarfaty C, Shabalina SA, Gottesman II, Ibba M, Sora I, Pasternak GW, Pan YX, Kieffer BL, Shaham Y, Gurevich E, Weinstein H, Saito T, Saido TC, Hempstead BL, Mogil JS, Sasaki T, Takada M, Yanagisawa M, Xu Y, Mori S, Matsuyama M, Hilliard MA, Murphy GJ, Tsien RW, Ando Y, Basbaum AI, Koob GF, Nagai H, Fujiwara M, Ji RR, Sudo Y, Befort K, Kase H, Ukai M, Zhao S, Gershon MD, Cai X, Tamura K, Yada T, Terauchi Y, Komatsu M, Ueno T, Hattori S, Matsunaga K, Pacher P, Koike K, Shiokawa D, Sakurai T, Kawasuji M, Yoshida S, Kaneko S, Kashiwagi K, Ushijima T, Arai H, Sekine Y, Hori S, Hirayama A, Katoh T, Satoh T, Saito Y,  Nakamura Y, Yamamoto K, Minami M, Satoh M. Human-Cannabinoid-Interaction Database: Insights into Cannabinoid Receptor Involvement in the Psychiatric Disorders. Biomolecules. 2019 Dec 12;9(12):758. doi: 10.3390/biom9120758. PMID: 31842280; PMCID: PMC6996930.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**